ArticleInfectious medicine2026
Convalescent plasma for persistent symptomatic COVID-19 infection in immune-suppressed patients - a case series.
Article in Infectious medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection progresses from an initial direct viral cell injury to an immune-mediated response. In most cases, the immune response results in viral clearance and recovery after a mild disease. Severe infections seem to result mainly from uncontrolled immune-mediated damage. Accordingly, initial treatment involves an antiviral strategy, while late severe infection is treated with anti-inflammatory medication. Immunocompromised patients have reduced vaccine efficacy and reduced ability to mount an appropriate immune response to SARS-CoV-2 infection, making them extremely susceptible to prolonged and severe infections. For these patients, standard treatment protocols need further investigation. In this retrospective case series, we investigated the effect of convalescent plasma and late antiviral treatment in twenty-three immunosuppressed patients, mostly pre-vaccinated (91%), presenting with symptomatic prolonged SARS-CoV-2 infection. All patients received initial antiviral treatment at the time of the first confirmed SARS-CoV-2 infection but continued to have symptoms. Convalescent plasma in addition to other treatments, including antivirals, resulted in significant improvement in 22 patients. Statistically significant improvement was detected in oxygen supplementation requirement (69.5% vs. 48%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.